Post hoc analysis of a phase 3 trial in resectable stage III NSCLC: of 314 operated patients, toripalimab plus chemotherapy vs placebo plus chemotherapy gave similar surgical complications, fewer cancelled operations (17.8% vs 26.7%) and more tumour downstaging (80.7% vs 50.7%).
Secondary analysisn = 404
Fang et al. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial